Promising GSK Heart Drug Misses Primary Endpoint In 15,000 Patient Trial

GlaxoSmithKline announced today that the first of two large pivotal phase 3 trials with a new drug, darapladib, had failed to meet its primary endpoint. Full results of the trial will be presented at a scientific meeting.

The STABILITY trial (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) tested the effect of darapladib, an investigational Lp-PLA2 inhibitor, in more than 15,000 patients with chronic coronary heart disease. GSK reported a nonsignificant 6% relative risk reduction associated with the use of darapladib in the time to first occurrence of any major adverse cardiovascular event (the composite of heart attack, stroke, and cardiovascular death).

Click here to read the full post on Forbes.

 

Leave a Reply

%d bloggers like this: